Pinos Elisabet de los - Feb 3, 2025 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role
President and Chief Executive Officer, Director
Signature
/s/ Conor Kilroy, as Attorney-in-Fact
Stock symbol
AURA
Transactions as of
Feb 3, 2025
Transactions value $
$0
Form type
4
Date filed
2/4/2025, 05:52 PM
Previous filing
Jan 21, 2025
Next filing
Feb 18, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AURA Common Stock Award $0 +194K +63.02% $0.00 503K Feb 3, 2025 Direct F1, F2
holding AURA Common Stock 128K Feb 3, 2025 By EdIP Revocable Trust F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AURA Stock Option (Right to Buy) Award $0 +256K $0.00 256K Feb 3, 2025 Common Stock 256K $7.68 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2026, subject to the Reporting Person's continued service as of each such vesting date.
F2 On November 7, 2023, the Reporting Person filed a Form 4 which incorrectly included an additional 3,649 shares in the amount of securities beneficially owned directly after the reported transaction and excluded 3,649 shares from the amount of securities beneficially owned indirectly after the reported transaction. The Reporting Person's holdings after the transactions reported on this Form 4 reflect this correction.
F3 The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.
F4 The shares underlying this option vest as follows: 25% of the shares vest on February 3, 2026 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Remarks:

President and Chief Executive Officer